-
14m 3s
-
17m 32s
-
12m 7sPart 1 | Session 5 The BIOVASC Trial with Dr Harriette Van Spall & Prof Roberto Diletti
-
5m 59sPart 2 | Session 1 Statins to Protect Heart During Cancer Treatment: The STOP-CA Trial
-
5m 38sPart 2 | Session 2 RENOVATE-COMPLEX-PCI: IVUS Vs OCT Optimisation in Complex PCI
-
8m 1sPart 2 | Session 3 Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study
-
5m 41s
-
3m 46s
-
5m 53s
-
3m 44sPart 2 | Session 7 MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients
-
5m 21sPart 2 | Session 8 Evaluation of the Mechanism of Benefit for Dapagliflozin in HFpEF
-
3m 7sPart 2 | Session 9 BMAD Trial: μCor in Ambulatory Decompensated Heart Failure
-
5m 44s
-
8m 2s
-
33m 36sPart 3 | Session 1 ACC.23 Late-breaking Science Wrap Up
-
22m 4sPart 3 | Session 2 What's Hot at ACC.23? Late-breaking Science Preview
-
16m 22s
-
5m 34sPart 4 | Session 2 Lipid Management & the CLEAR Trial with Dr Erin Michos
-
17m 7sPart 4 | Session 3 Obesity Management Strategies in 2023 with Dr Harold Bays
-
15m 9sPart 4 | Session 4 ACC.23 President Interview with Dr B Hadley Wilson
-
1m 17sPart 5 | Session 1 Dr Akowuah: Cardiovascular Research & Message for Early-Career Researchers
-
1m 22sPart 5 | Session 2 Dr Kini: Asking Questions & Her Motivation to Do Research on Plaque
-
5m 29s
-
1m 21sPart 5 | Session 4 Dr Verma: Passion for Electrophysiology & His Advice For Young Researchers
-
3m 33s
-
31sPart 5 | Session 6 Dr Hahn: Innovative Areas of Cardiovascular Science in 2023
-
1m 33sPart 5 | Session 7 Dr Forrest: Structural Heart Innovations and Advice to Young Researchers
-
16m 12sPart 1 | Session 1 The CLEAR-Outcomes Trial with Dr Harriette Van Spall & Dr Steven Nissen
ACC.23/WCC — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by principle investigator, Dr Divaka Perera (King’s College London & Guy’s & St Thomas’ Hospital, UK) and investigator, Dr Peter O'Kane (Royal Bournemouth Hospital, UK) to discuss the REVIVED-BCIS2 viability analysis (NCT01920048).
This analysis of the REVIVED-BICS2 trial found that viability characterisation does not impact the effect of PCI on prognosis or LV recovery in ischaemic cardiomyopathy, compared to optimised guideline therapy (OMT) alone. The study also showed that scar burden can predict prognosis and likelihood of LV recovery in ischaemic cardiomyopathy independent of baseline LVEF or extent of CAD.
Recorded remotely from Hamilton, London and Dorset, 2023.
Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data.
For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
More from this programme
Part 1
Late-Breaker Discussion Series
Part 2
Expert Interviews
Part 3
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023.
Part 4
Highlights Reviews
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Divaka Perera
Prof Divaka Perera is a Professor of Interventional Cardiology in the School of Cardiovascular Medicine & Sciences and an Honorary Cardiologist at Guy’s and St Thomas’ Hospital. He graduated in medicine from Cambridge University, undertook cardiology specialist training in London and Sussex and received a Clinical Senior Lectureship Award from the Higher Education Funding Council for England in 2008. In 2013, he received the BCS Michael Davies Early Career Award for contribution to cardiovascular science.
He runs a translational research programme into the mechanisms and consequences of reduced blood supply to the heart muscle in chronic coronary artery disease, acute myocardial infarction and valve disease. He is also involved in designing and performing multicentre clinical trials to evaluate novel treatments for patients with ischaemic heart disease. He is the chief investigator of the NIHR-funded UK multi-centre randomised control trial REVIVED, which seeks to…
Peter O’Kane
Consultant Interventional Cardiologist
Dr Peter O'Kane has been Editor-in-Chief of Interventional Cardiology: Reviews, Research, Resources (ICR3) since July 2021.
Dr Peter O’Kane was appointed as a consultant interventional cardiologist at Royal Bournemouth Hospital in July 2007 and has performed more than 7000 PCI cases. He has extensive experience with coronary physiology and intra-coronary imaging to guide intervention and the many tools and techniques to manage bifurcations, calcification and chronic occlusions.
Dr O'Kane has given his permission to be contacted here.
Comments